Hanson Josh, Radlof Sharna, Littlejohn Margaret, Hempenstall Allison, Edwards Ros, Nakata Yoko, Gregson Sandra, Hayes Richard, Smith Simon, McKinnon Melita, Binks Paula, Tong Steven Y C, Davies Jane, Davis Joshua S
Cairns and Hinterland Hospital and Health Service, Cairns, Queensland, Australia.
The Kirby Institute, UNSW, Sydney, New South Wales, Australia.
Intern Med J. 2024 Apr;54(4):647-656. doi: 10.1111/imj.16181. Epub 2023 Aug 7.
The prevalence of chronic hepatitis B (CHB) in Aboriginal and Torres Strait Islander Australians in Far North Queensland (FNQ) is greater than twice that of the general Australian population. CHB is common in Torres Strait Islanders diagnosed with hepatocellular carcinoma (HCC) - and in Aboriginals with HCC living in the Northern Territory - however, Aboriginals diagnosed with HCC in FNQ very rarely have CHB. The explanation for this apparent disparity is uncertain.
To determine the HBV genotypes in the FNQ Aboriginal and Torres Strait Islander population and their correlation with clinical phenotype.
We determined the HBV genotype of Aboriginal and Torres Strait Islander Australians living with CHB in FNQ and correlated this with demographic and clinical findings.
134/197 (68%) enrolled individuals had a sufficient viral load for genotyping. All 40 people with HBV/D genotype had Aboriginal heritage, whereas 85/93 (91%) with HBV/C had Torres Strait Islander heritage (P < 0.0001). Individuals with HBV/D were younger than those with HBV/C (median (interquartile range) age: 43 (39-48) vs 53 (42-66) years, P = 0.0002). However, they were less likely to be HBeAg positive (1/40 (3%) vs 23/93 (25%), P = 0.001). All three HCCs developed in Torres Strait Islanders; two-thirds were infected with HBV/C14; genotyping was not possible in the other individual. All 10 diagnoses of cirrhosis occurred in Torres Strait Islanders, 6/10 were infected with HBV/C14, genotyping was not possible in the other four individuals.
HBV genotypes in Aboriginal and Torres Strait Islander Australians in FNQ differ markedly, which could explain the significant differences in the clinical phenotype in the two populations and might be used to inform cost-effective CHB care in the region.
在昆士兰远北地区(FNQ)的澳大利亚原住民和托雷斯海峡岛民中,慢性乙型肝炎(CHB)的患病率是澳大利亚普通人群的两倍多。CHB在被诊断为肝细胞癌(HCC)的托雷斯海峡岛民中很常见,在居住于北领地的患HCC的原住民中也很常见,然而,在FNQ被诊断为HCC的原住民中,很少有人患有CHB。这种明显差异的原因尚不确定。
确定FNQ原住民和托雷斯海峡岛民人群中的HBV基因型及其与临床表型的相关性。
我们确定了FNQ地区患有CHB的澳大利亚原住民和托雷斯海峡岛民的HBV基因型,并将其与人口统计学和临床发现相关联。
197名登记参与者中有134名(68%)的病毒载量足以进行基因分型。所有40名HBV/D基因型感染者均有原住民血统,而93名HBV/C基因型感染者中有85名(91%)有托雷斯海峡岛民血统(P<0.0001)。HBV/D基因型感染者比HBV/C基因型感染者年轻(年龄中位数(四分位间距):43(39 - 48)岁对53(42 - 66)岁,P = 0.0002)。然而,他们HBeAg阳性的可能性较小(1/40(3%)对23/93(25%),P = 0.001)。所有3例HCC均发生在托雷斯海峡岛民中;其中三分之二感染了HBV/C14;另一例无法进行基因分型。所有10例肝硬化诊断均发生在托雷斯海峡岛民中,10例中有6例感染了HBV/C14,另外4例无法进行基因分型。
FNQ地区澳大利亚原住民和托雷斯海峡岛民的HBV基因型存在显著差异,这可以解释这两个人群临床表型的显著差异,并可能用于为该地区具有成本效益的CHB治疗提供参考。